This bibliometric analysis aimed to map the global research landscape and innovations for glioma in elderly patients, identifying knowledge gaps and interdisciplinary innovations. The study systematically searched the Web of Science Core Collection, identifying 1,299 relevant publications, and reviewed randomized controlled trials from PubMed to assess clinical progress. Analysis was performed using CiteSpace and VOSviewer to examine temporal trends, contributions by countries and institutions, collaboration networks, journal impact, co-citations, keyword clusters, and emerging research frontiers. Results showed annual publications increased 4.3-fold from 2001 to 2025. The leading contributing countries were the U.S. (32.8%), Italy (12.4%), and Germany (11.0%). Key institutions included the University of Zurich and Mayo Clinic. The analysis identified three phases of research evolution: histopathological classification (2001–2013), therapy standardization with radiotherapy/temozolomide (2014–2018), and molecular stratification focusing on MGMT methylation (2019–2025). Keyword clustering highlighted aging-related priorities such as surgical management, geriatric assessment, and molecular phenotypes. The study concludes that significant gaps persist in elderly glioma research, particularly regarding age-related comorbidities and molecular heterogeneity. While clinical trials have established treatment frameworks, future studies should integrate geriatric assessments, tumor microenvironment dynamics, and cross-disciplinary approaches. The dominance of Western institutions underscores opportunities for global collaboration, especially with rapidly aging nations.
If you're an older adult diagnosed with a brain tumor called glioma, the research guiding your care has a major blind spot. These tumors behave differently and are more aggressive in older people, yet the scientific world has been slow to catch up. A new analysis of over 1,200 studies shows that while research has grown more than fourfold since 2001, it's still not enough. The work is led by a few countries like the U.S., Italy, and Germany, and has evolved from basic classification to standardizing treatments like radiation and chemotherapy. More recently, scientists have started looking at the tumor's molecular details, like a specific genetic marker called MGMT methylation. However, the analysis reveals persistent and significant gaps. We don't know enough about how common age-related health problems interact with these tumors or how to account for the unique biology in older patients. While clinical trials have set up basic treatment frameworks, the future needs to bring together cancer specialists and geriatric experts. The dominance of Western institutions also means we're missing crucial perspectives from other rapidly aging nations around the world.
What this means for you: Brain tumor research for older adults is growing but has critical gaps in understanding age, health, and biology.
View Original Abstract ↓
ObjectiveGlioma demonstrates age-specific molecular profiles and heightened aggressiveness in older adults, yet research remains predominantly focused on younger populations. Amid global aging and rising incidence, tailored therapeutic strategies for elderly patients are urgently needed. This study provides a comprehensive bibliometric analysis of scientific literature on glioma in the elderly, aiming to map research output, identify knowledge gaps, and highlight interdisciplinary innovations.MethodsWe conducted a systematic search in the Web of Science Core Collection, finding 1,299 relevant publications, and reviewed randomized controlled trials from PubMed to assess clinical progress. We used CiteSpace and VOSviewer to analyze temporal trends, contributions by countries and institutions, collaboration networks, journal impact, co-citations, keyword clusters, and emerging research frontiers.ResultsAnnual publications increased 4.3-fold from 2001 to 2025. The U.S. (32.8%), Italy (12.4%), and Germany (11.0%) were the leading contributors. Research evolution progressed through three phases: histopathological classification (2001–2013), therapy standardization with radiotherapy/temozolomide (2014–2018), and molecular stratification focusing on MGMT methylation (2019–2025). Key institutions included the University of Zurich and Mayo Clinic. Keyword clustering highlighted aging-related priorities such as surgical management, geriatric assessment, and molecular phenotypes.ConclusionSignificant gaps persist in elderly glioma research, particularly regarding age-related comorbidities and molecular heterogeneity. While clinical trials have established treatment frameworks, future studies should integrate geriatric assessments, tumor microenvironment dynamics, and cross-disciplinary approaches. Dominance by Western institutions underscores opportunities for global collaboration, especially with rapidly aging nations.